Close Menu

A candidate SARS-CoV-2 vaccine from Novavax is about 90 percent effective in preventing COVID-19 in a trial conducted in the UK, the New York Times reports. However, it has an efficacy rate of less than 50 percent in a trial in South Africa, where a new viral variant has been found.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.